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Abstract 
 
 
Background-aims: The clinical benefit of sorafenib in patients with 
hepatocellular carcinoma (HCC) has been undervalued due to the absence of 
complete responses even though patients who develop early dermatologic 
reactions have shown very positive outcome. In addition, sorafenib is described 
as an antiangiogenic drug, but it also acts on immunological cells. Thus, the aim 
is to assess the complete response rate in a retrospective cohort of HCC 
patients treated with sorafenib and to describe the profile of the patients who 
achieve complete response in order to identify factors related to this event and 
their connection with the immunological profile of sorafenib.  
Methods: Ten Spanish centres submitted their cases of complete response 
under sorafenib. The baseline characteristics, development of early 
dermatologic reactions and cause of treatment discontinuation were annotated. 
Radiological images pre-sorafenib, at first control, after starting sorafenib, at the 
time of complete response and at least 1 month after, were centrally reviewed. 
Results: 20/1119 patients had been classified as complete responders by the 
centres, but 8 were excluded after central review. Ten patients had complete 
disappearance of all tumor sites and two had just a small residual fibrotic scar. 
Thus, 12 patients were classified as complete responders [58% HCV, median 
age 59.7 years, 83.4% Child-Pugh A, ECOG-PS 0 91.7% and BCLC-C 
83.3%].Median overall survival and treatment duration were 85.8 and 40.1 
months respectively.  All but one patient, developed early dermatologic 
reactions and 7 patients discontinued sorafenib after achieving complete 
response due to adverse events, patient decision or liver decompensation. 
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Conclusion: Complete response affects 1% of the patients. Its association with 
early dermatologic reactions supports the role of a specific 
immune/inflammatory patient profile in the improved response to sorafenib.  
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Introduction 
Sorafenib is the first-line systemic treatment for patients diagnosed with 
hepatocellular carcinoma (HCC). Patients who develop early dermatologic 
adverse events (eDAE)- defined as dermatological adverse events developed 
within the first 60 days after starting sorafenib (DAE60)- present better overall 
survival (OS) than patients who start sorafenib but do not develop these 
reactions (18.2 months vs 10.1 months; respectively)(1,2). This association can 
be explained by the biological link between hypoxia (which could be enhanced 
by sorafenib) and inflammation(3). Thus, even though sorafenib is presented as 
an anti-angiogenic and anti-proliferative drug, the exact mechanism of action is 
unknown. 
Sorafenib has proven to be effective in patients who may not benefit from 
options of higher priority such as surgery, ablation or transarterial 
chemoembolization. However, the clinical benefit of sorafenib treatment for 
HCC patients is frequently undervalued because the rate of objective response 
according to conventional criteria(4) is low, both in the pivotal trials(5,6) and in 
cohort investigations(7–9). By contrast, interventions that reduce tumor burden 
through resection or induction of tumor necrosis (ablation, chemoembolization, 
radioembolization) offer such results although they may not offer better survival 
or may even provide a shorter life expectancy according to published data(10).    
Interestingly, during the last 9 years several clinical cases and case series of 
HCC patients have described objective responses under sorafenib and also 
complete response (CR). These are described in Table 1, but the response 
criteria used to evaluate the patients in those publications is heterogeneous 
(RECIST v1.0(11)); RECIST 1.1(4); mRECIST(12) and/or WHO(13). Thus, we 
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decided to retrospectively evaluate the rate of CR under sorafenib in a 
multicenter study in Spain. 
Patients and methods   
This is a multicentre retrospective study including HCC patients treated with 
sorafenib between October 2007 and March 2014, with the aim of evaluating 
patients who achieved CR according to RECIST v1.1 plus SHARP trial criteria 
amendments(14) that were implemented to properly define additional nodules in 
the setting of cirrhosis and avoid the registration of ascites and pleural effusion 
as progression if not proven by cytology. We did not consider the use of 
necrosis as per EASL criteria. 
All patients who were treated with sorafenib in each centre regardless of 
whether they achieved CR or not, represented the initial study cohort. Each 
centre submitted the cases that had been classified locally as complete 
responders, but only those patients who were confirmed to have achieved CR 
after central review were considered in our final cohort population for the study. 
The inclusion criteria were: (1) HCC diagnosed by either pathology or by non-
invasive criteria according to AASLD guidelines(15) and EASL guidelines(16); 
(2) patients under sorafenib treatment or patients who discontinued sorafenib 
treatment due to adverse events but who had not received an additional 
treatment after complete radiological response under sorafenib according to 
RECIST v1.1(4).  
The exclusion criteria were: (1) concomitant oncologic treatment prior to CR; (2) 
Absence of complete radiological response according to RECIST 1.1 criteria 
(12,17); (3) HCC treatment after complete response achieved under sorafenib. 
Radiological criteria for baseline assessment and tumor response: 
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At the time of diagnosis, HCC lesions were divided as target and non-target 
lesions following RECIST 1.1 criteria(4). Portal or hepatic vein thrombosis was 
considered malignant if it was biopsy proven and/or displaying arterial 
enhancement on either computed tomography (CT), Magnetic Resonance (MR) 
or contrast enhanced ultrasound (CEUS), and/or if it expanded the diameter of 
the portal or hepatic vein and had close relation with HCC in the liver 
parenchyma. 
The criteria used for assessing radiological complete response have been 
summarized before and the two central radiologists validated its presence. 
Because some patients may present residual lesions after CR we also 
registered CR when observing 1) the persistence of small (<2 cm) residual 
lesion replacing the initial infiltrative HCC showing a scar-like appearance 
(peripheral, non-arterial enhancement pattern but non- or minimal late 
enhancement, wedge-shaped and with capsular retraction); or 2) unequivocal 
reduction of extension and diameter of the thrombus with persistence of a thin 
residual chronic fibrotic-like hypodense non-enhancing thrombus. Furthermore, 
to be considered residual these lesions had to remain stable for a period of 2 
years, ensuring its non-malignant behavior. 
Data collected for the analysis: 
The variables collected for the analysis were baseline demographic patients’ 
characteristics, radiological images at 4 time points (pre-sorafenib, first control 
after starting sorafenib, at the time of CR and at least 1 month after CR to 
confirm it), presence of dermatologic adverse events within the first 60 days of 
sorafenib treatment, reason for sorafenib discontinuation and status at the end 
of follow-up (death/alive). 
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The radiologic evaluation including number of lesions, size at each time point 
and response evaluation according RECIST 1.1(4) was done centrally by 2 
independent radiologists with more than 10 years of experience each in the field 
of HCC (JR and AD). 
Endpoints of the study 
The primary end point of this study was to evaluate the rate of CR in this 
multicentre Spanish cohort and analyze the profile of patients who achieved CR 
under sorafenib treatment, including the development of EDAE days of 
treatment) during sorafenib treatment. 
Treatment 
The starting sorafenib dose and dose adjustments were done according to the 
clinical practice recommendations (15,16,18,19) that closely parallel the 
manufacturer’s recommendations.  
Statistical analysis 
Categorical variables are described as frequencies and percentages and 
continuous variables as median and ranges. Survival rates and curves were 
determined using the Kaplan–Meier method. Last date for data collection was 
October 14, 2016. Analysis was done censoring survivals at the time of last 
follow-up or at time of starting an additional HCC treatment. All calculations 
were done with SPSS package version 22 (SPSS Inc., Chicago, IL). 
 
RESULTS: 
Between October 2007 and March 28, 2014, 1119 HCC patients were treated 
with sorafenib in 13 referral centres across Spain. Ten of these centres had at 
least one patient with CR according to their local radiological evaluation, so that 
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twenty patients were initially registered locally as CR. However, 8 patients were 
excluded either because of lack of fulfilment of diagnostic criteria so no 
conclusive diagnosis could be done prior to treatment (3 cases), target lesion 
treated simultaneously with radiofrequency or resection (2 cases) and non-
confirmed CR at central radiology review according to RECIST 1.1(3 cases) 
(Figure 1). One of these two patients had iso-enhancing lesions on Magnetic 
Resonance (MR) dynamic sequences, but lesions were still identified on T2 and 
pre-gadolinium T1 sequences. The second patient had hypoenhancing lesions 
on CT scan as an effect of sorafenib and was classified at his centre as 
complete response because of potential full necrosis and hence, was 
considered a complete responder when applying the mRECIST criteria. Of the 
remaining 12 patients, 10 of them had complete resolution of all malignant 
lesions according to RECIST 1.1 (Figure 2), and two additional patients had one 
small peripheral residual lesion stable for a period of at least 2 years. At 
baseline, these patients had large infiltrative tumors measuring 11 cm and 4,3 
cm with tumoral portal vein thrombosis respectively and, after treatment with 
sorafenib, imaging displayed small areas (21 and 12 mm in size) without 
contrast enhancement that were classified as residual fibrotic areas 
(Supplementary Figure 1 and supplementary Figure 2). 
The baseline characteristics of the 12 patients with confirmed CR are 
summarized in Table 2. Nine of them were men (75%) and 3 women (25%). 
Median age was 59.7 years [49.8-78]. The most common cause of underlying 
liver cirrhosis was Hepatitis C Virus (58.3%), followed by Hepatitis B Virus 
(16.7%), alcohol-induced liver disease (16.7%) and other causes (8.3%). Liver 
function was preserved in most of the patients: 83.4% corresponded to Child-
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Pugh A, 8.3% were Child-Pugh B and 8.3% were non-assessable because of 
absence of cirrhosis. 91.7% were asymptomatic (ECOG-PS 0) and 8.3% 
presented mild cancer-related symptoms (ECOG-PS 1). In terms of tumor 
stage, 2 patients corresponded to BCLC B and 10 to BCLC C (83.3%). Vascular 
invasion was identified at CT or MR in 66.7% of patients, and 16.7 % presented 
extrahepatic spread. 
Radiological evaluation:  
The baseline radiological characteristics of the 12 patients finally included in the 
study are summarized in Table 3. Five patients had nodular type HCC at 
baseline, three infiltrative type and the remaining four patients had both 
infiltrative lesions on one hepatic lobe and nodular type on the other. Among the 
patients with nodular lesions, the number of lesions in the liver ranged from 0 
(extrahepatic metastatic spread) to 8 (median, 1 lesion). The tumor size of 
nodular lesions ranged from 19 to 75 mm (median, 32 mm). 
The seven patients with infiltrative HCC had expansive vein thrombosis 
whereas in those with nodular type only one patient had portal vein thrombosis. 
Only two patients had extra-hepatic disease, one with lung metastasis and 
another one with peritoneal recurrence after surgery on the right subphrenic 
region after right hepatectomy without residual lesions on the liver. No patient 
had radiological signs of lymph node invasion according to the criteria used for 
the SHARP trial(5). 
The median time between baseline CT scan and the achievement of 
radiological CR was 6 months (range 1.4 – 16.1 months).  
Analysis according to RECIST 1.1 plus protocol amendment: 
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In 2 out of the 20 patients (10%) initially sent for central evaluation, both central 
readers identified the presence of small residual scar-like lesions in the 
subcapsular region of the liver which remained stable over a period of 2 years 
while the patient was under sorafenib treatment. The first patient had at 
baseline a nodular lesion of 110 mm that decreased in size (21 mm) but 
persisted as such small lesion together with the presence of new peripheral 
calcification. The second patient had at baseline a 43 mm nodular lesion, an 
infiltrative HCC and an expansive portal vein thrombosis. In addition to the 12 
mm residual scar-like lesion, a residual non-expansive portal vein thrombosis 
was also identified (Supplementary figure 1 and supplementary figure 2). 
According to RECIST 1.1 criteria these patients cannot be classified as CR, but 
the radiological characteristics and morphological changes of these lesions, and 
especially their stability over time, favors the classification of these patients as 
complete responders. 
Clinical outcome, treatment duration and overall survival: 
Sorafenib was initiated at full dose (800 mg/day) in the whole cohort except in 
one patient. His attending physician started at half dose because of concerns 
about potential interaction with concomitant anticoagulant treatment. All but one 
(91.6%) of the patients developed dermatologic adverse events within the first 
60 days of treatment. The patient without early dermatologic adverse events 
corresponds to the one that initiated sorafenib at half dose. 
At the time of CR registration, four patients (33.4%) were treated at 800 mg per 
day, one (8.3%) patient at 600 mg per day, three of them (25%) at 400 mg per 
day, one (8.3%) at 200 mg per day and three (25%) of them were without any 
kind of treatment due to definitive interruption as per patient decision.  
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The median overall survival was 85.8 months (IC 95% 67.8 – 103.8). Median 
treatment duration and median time from sorafenib initiation to documented CR 
was 40.1 months (range 7.6 – 83.6) and 13.3 (range 0.9 – 33.3) respectively.   
At the end of the follow-up, 4 patients continued on treatment and did not 
present tumoral recurrence, and 7 discontinued sorafenib after achieving CR (3 
due to vascular events, 2 as a result of patient decision and 2 due to liver 
decompensation). Five of those who discontinued developed HCC recurrence 
after sorafenib interruption and the other 2 continue under CR. Median time 
since sorafenib discontinuation and tumoral recurrence was 16.9 months (range 
8.5 – 73). Regarding the pattern of recurrence in these patients, one presented 
extrahepatic spread involving lymph nodes and lung metastasis, another 
developed intrahepatic spread and tumoral portal vein thrombosis and three of 
them presented intrahepatic spread. One patient developed HCC recurrence 
after 28.02 months of achieving CR under sorafenib.  
Nine out of the twelve patients had increased AFP baseline levels. In 8 of them 
the levels returned to normal, while in one case AFP decreased from 3100 
ng/dL to levels below 150 ng/dL. Regarding the 2 patients with residual fibrotic 
lesions that would have been registered as CR despite not fully fitting into the 
RECIST criteria the AFP data were as follows: one of them had increased AFP 
levels at baseline (155 ng/dL), achieving normalization when complete 
response was documented (4.4 ng/dL), and the other patient had normal AFP 
value at baseline (6 ng/dL) and AFP levels remained normal when CR was 
achieved (4 ng/dL). Figure 3 
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Discussion: 
This multicentre observational study conducted after a nationwide survey in 
Spain, which considered 1119 patients treated with sorafenib, describes the 
clinical and radiological characteristics of 12 HCC patients that achieved CR 
while on treatment. It is worth recalling that our cohort includes patients with 
advanced disease as reflected by their BCLC stage. 
The main issue in the CR evaluation is the criteria used for that evaluation. It is 
already known that the rate of radiological tumour progression in patients under 
sorafenib or regorafenib is similar between the different criteria used(20–22). 
However, these criteria differ in the rate of patients classified as CR, partial 
response or stable disease. Thus, to rule out the risk of a false positive 
diagnosis of CR we did a central revision and excluded 15 % of the original 
cohort (3 out of the 20 patients evaluated) due to non-confirmed CR at central 
radiology review according to RECIST 1.1 even when considered as complete 
responders by the local centre. 
Complete responses were not registered in the sorafenib pivotal trials(5,6) but 
several reports have described such positive evolution in a small number of 
patients (Table 1).  Our study offers a 1.07% CR rate that fits into an event that 
is not frequent at all, but that may occur in some fortunate individuals. Shiba et 
al reported a 0.6 CR rate in their countrywide Japanese study including 3047 
patients(23).  
The main difference between Shiba and our study was the definition of CR. 
They defined as complete responders patients with absence of contrast uptake 
within the tumor at dynamic imaging (mRECIST criteria). While necrosis is easy 
to be recognized after ablation or chemoembolization, it is more challenging and 
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controversial to do so when under sorafenib treatment. For these reasons we 
decided to adhere to RECIST 1.1 and avoid criteria that consider tumor density 
as a reflection of necrosis. Overall, if we apply the mRECIST definition for CR 
the prevalence of CR would be higher than it actually is. Indeed, this is one of 
the controversial points in the Lencioni et al study(24,25). 
As is well known, sorafenib is a powerful vasoconstrictor, as is the case with all 
antiangiogenics and this implies a reduction in hepatic artery blood flow that 
may result in hypodensity within the tumor nodules. While a correlation between 
supposed necrosis at radiology after ablation and pathology findings does exist, 
no such study is available for systemic therapy and specifically, for sorafenib.  
In addition to the cases fitting into the RECIST 1.1 definitions, we registered as 
complete responders 2 additional patients in whom all radiology findings and 
follow-up monitoring strongly supported the achievement of complete tumor 
eradication. If these 2 cases were not included, the CR rate would decrease to 
0.9% but still be informative and key to increasing our understanding. 
In the present study, in all but one of our patients (92%) the clinical record 
registered the emergence of early dermatologic adverse events. In the study by 
Shiba et al.(23) the prevalence of dermatologic adverse events in patients with 
CR was lower (45%) but still significantly higher than that in those without CR 
(patients who did not present CR (3%; p< 0.001) which means they presented 
PR, SD or progression.   
Thus, on-target sorafenib toxicity may have a predominant but underestimated 
role in the prediction of outcome. In this regard, we reported that the DAE60 is a 
predictor of better OS and Branco et al externally validated this data. Indeed, 
the median risk of death reduction in patients who developed eDAE is 42%, 
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higher than that reported in the whole cohort of the SHARP trial (35 %).  But, 
the role of the eDAEs is even more important, if we consider the absence of 
correlation between TTP and OS in the SHARP and Asian Pacific-data. In this 
regard, the impact of eDAEs is maintained regardless of the radiological tumour 
progression. 
Thus, our results reinforce the association between eDAEs and better outcome 
but even more important they can be a link between clinical events and the 
understudied sorafenib mechanism of action. 
The mechanism for the benefits associated to dermatologic adverse events is 
unknown but are very likely related to an immune modulation induced by any of 
the targets affected by sorafenib. This drug may modulate the stromal cell 
population and this may prime several molecular events due to direct action or 
mediated by reduced blood flow reaching tumor cells(26). Hypoxia activates 
nuclear factor κB (NF-κB), which in turn increases the production of tumor 
necrosis factor α (TNF-α), a pro-inflammatory cytokine, but simultaneously 
attenuates apoptosis. Additionally, interactions between hypoxia and 
inflammation are seen as a regulatory component of NF-κB and of the 
regulation of hypoxia-inducible factor-1α (HIF-1α) transcription by NF-κB before 
and during inflammation (3). Thus, members of the NF-κB family of transcription 
factors regulate inflammation and score the immune responses and tissue 
homeostasis (27,28). HIF-1α regulates several functions of myeloid-derived 
suppressor cells (MDSCs) (29) and allows myeloid cells to generate ATP in 
oxygen-deprived tissues. Lei et al evaluated the change of the peripheral blood 
immune pattern and its correlation with prognosis in patients with liver cancer 
treated with sorafenib. They reported a higher ratio of B cells and regulatory B 
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cells in PBMC of patients in the response group  (SD or CR) than in that of the 
non-response group(30).  
Interestingly, recent phase 1-2 data using different immune modulators blocking 
immune checkpoints have offered promising data regarding antitumoral activity 
and primed a major expectancy in the success of such therapies that needs to 
be confirmed in adequately powered phase 3 trials. In fact, a 2% rate of 
complete response has been reported in the still preliminary data with 
nivolumab in a cohort of 262 patients(31) and 3.3% (1/30 patients) in HCV, 2.3 
% in HBV (1/43 patients) and 0% in uninfected patients (0/72 patients)(32), 
which is very similar to the rate reported in this manuscript. 
However, if hope is the driver for decision making, the rate offered by our 
results and those by Shiba et al(23) should serve to expose that the expectation 
for long-term disease- free survival is not absent with sorafenib. It could be 
argued that the complete responses observed could be just spontaneous 
regressions of HCC as has been published by several authors, us among 
them(33). The rate is higher than what is observed if summing up all the 
placebo control arms of the different trials that have been performed in recent 
years. This exercise shows a 0.008% rate of complete responses in the placebo 
arm (supplementary table 1) and hence, the rate under sorafenib appears 
higher. Furthermore, the same favourable spontaneous evolution could be 
suggested in those patients with encouraging long-term outcome after resection 
or TACE.  
Our cohort encompasses a heterogeneous group of patients with different 
radiological patterns of HCC, including nodular, infiltrative or mixed HCC 
lesions. Interestingly enough, 66.7% (8/12) presented expansive portal vein 
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thrombosis and 2 out of 12 presented extra-hepatic lesion but this was not a 
limitation to achieve a CR. 
Thus, the main question in clinical practice is whether sorafenib should be 
stopped upon detection of complete response or if treatment should be kept in 
place without time limits. There is no answer to this question but our data 
suggest that clinicians should be very careful and critically assess all aspects. 
The first issue is to secure that initial diagnosis is 100% accurate and complete 
response is reliable. In our study we discarded three cases because of the 
absence of a target lesion and three additional cases because local readers 
initially classified them as complete responders. This was due to the application 
of the mRECIST criteria which have not been validated at all for systemic 
therapy, and may be faulty to register necrosis. In such cases the follow-up data 
showed disease progression in the next 3 to 6 months after registering the 
supposed CR. Hence, it is likely that such assessment was an overestimation. 
After securing the existence of CR it is important to retain that we had only one 
recurrence in patients kept under treatment, while recurrence was observed in 5 
of the 7 cases in which the drug was interrupted. According to these 
observations, it seems sound to keep sorafenib in place until intolerance or 
adverse events promote its interruption.  
In summary, our study exposes that around 1% of the patients with advanced 
HCC treated with sorafenib achieve a long-lasting complete response as 
reflected by a complete disappearance of all tumor sites. This is probably 
mediated through immune reactivation mediated by the drug as reflected by the 
significant association with the development of dermatologic adverse events. 
These findings, together with the recent description of high risk of tumor 
Page 21 of 38
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
recurrence after antiviral therapy, indicate the major role of immune surveillance 
in cancer control and thus, supports the ongoing investigation in this field in 
HCC patients.  
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Figure 1 HCC: Hepatocellular Carcinoma. CR: Complete Response. 
 
Figure 2 
Computed tomography of an ill defined-infiltrative hepatocellular carcinoma 
located on segments IV and VIII of the liver. The arterial phase (figure 2a) 
shows areas of heterogeneous enhancement (arrowheads) that displays 
scattered areas of washout on portal venous phase (arrowheads in figure 2b). 
There was an expansive portal vein thrombosis, better seen on coronal 
reconstruction (arrow in figure 2c). 
During Sorafenib treatment, the mass has vanished, persisting a wedge-shaped 
area of arterial enhancement (arrowheads in figure 2d) with no washout related 
to residual non-expansive portal vein thrombosis (arrow in figure 2e). 
 
Figure 3 
AFP evolution before starting sorafenib, at first control, when CR was 
documented and after achieving CR. 
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Author, Journal & Year n Etiology CPS PVT M1 PS BCLC DAE DAE60 
Tumor 
response 
criteria 
So BJ et al. J Hematol Oncol 2008 1 Hemochromatosi NR No Lung 2 D No NR NR 
Wang SX et al. Target Oncol 2010 1 HCV A Yes NR NR C No NR NR 
Kudo M et al. Oncology 2010 2 HBV A Yes Lung NR NR NR NR Pathologic 
Chelis L et al. Med Oncol 2011 1 HBV + HIV No LC No No 0 C Yes NR NR 
Inuzuka T et al. Oncology 2011 1 HCV A No Lung 1 C No NR NR 
Sacco R et al. BMC Gastroenterol 2011 1 HCV A Yes No 0 C Yes NR RECIST 
Abbadessa G et al. World J Gastroenterol 
2011 1* HCV A Yes NR 0 C Yes Yes NR 
Mizukami H  et al. Case Rep Oncol 2012 1 HCV NR No Lymph NR C Yes Yes RECIST 
Ahn SY  et al. Dig Dis Sci 2013 1 HBV A Yes NR NR C NR NR NR 
Gerardi A et al.Oncol Lett 2013 1 HCV A Yes No NR C Yes NR RECIST 
Hagihara A et al.Intern Med 2013 1 HCV B Yes Lung 3 C No NR NR 
Kee KM et al. Onco Targets Ther 2014 1 Cryptogenic A Yes NR NR NR Yes Yes mRECIST 
Shiozawa K et al. Oncol Lett 2014 1 HCV A Yes NR NR C Yes Yes mRECIST 
Shiba S et al. Hepatol Res 2014 18 HCV:83,3% HBV:16,7% 
A:88.8% 
B:11.2% 17% 44%** 
0:77.8% 
1:22.2% NR 
83%*
** 
NR mRECIST 
Moroni M et al. Future Oncol 2015 1 HCV A Yes No 0 C Yes NR NR 
Shinoda M et al. World J Surg Oncol 2015 1 Cryptogenic A Yes Lung NR NR No NR RECIST 
Azmi AN et al. J Dig Dis 2015 1 HCV A Yes No 2 NR Sí NR NR 
Katafuchi E et al. Case Rep Gastroenterol 
2015 1 HCV A No Lung NR NR No No RECIST 
Park JG et al. Clin Mol Hepatol 2015 7 
HBV:57.1% 
HCV:28.6% 
OH + HBV: 
14.3% 
A:57.1% 
B:42.9% 
Y:85.7
% 
N:14.3
% 
Y:14.3% 
N:85.7% 0 C No No mRECIST 
Maida M  et al. J Gastrointestin Liver Dis 
2016 1 OH A Yes No 0 C No No 
mRECIST+ 
RECIST 
Simao A et al.Acta Med Port 2016 1 OH + VHB + VHC A Yes 
Lung + 
adrenal NR C No No mRECIST 
CPS: Child-Pugh Score. PVT: Portal Vein Thrombosis. PS: Performance Status. DAE: Dermatologic Adverse Events.  
EDA: Early Dermatologic Adverse Events. N: Number of patients; BCLC:  Barcelona Clinic Liver Cancer; PVT: Portal Vein Thrombosis; PS: 
Performance Status; HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus; RECIST: Response Evaluation 
Criteria in Solid Tumors; mRECIST: Modified RECIST. LC: Liver Cirrhosis. NR: Not Reported. M1: Metastases. Y: Yes. N: No. 
*Only in one patient out of four all information was available 
**Lymph nodes 22%, lung 39%. 
*** 83% Hand-Foot skin reaction, 34% rash, 56% alopecia. 
Table 1: Clinical cases and cohort studies of patients treated with sorafenib who 
developed complete radiological response. 
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 N = 12 
Age, median value [range] (years) 59.7 [49.8-78] 
Men/Women, % 75/25 
Etiology HCV/Alcohol/HBV/Others, % 58.3/16.7/16.7/8.3 
Child-Pugh A/B/NA, % 83.4/8.3/8.3 
BCLC B/C, % 16.7/83.3 
ECOG-Peformance Status (0/1) 91.7/8.3 
Macrovascular invasion (Yes/No), % 66.7/33.3 
Extrahepatic spread (Yes/No), % 16.7/83.3 
Bilirrubin mg/dL, median value [range] 0.8 [0.4-1.3] 
Albumin g/L,  median value [range] 39.5 [32-51] 
Prothrombin Time, % [range] 95 % [71-100] 
Alpha-fetoprotein ng/mL, median value [range] 5306.7 [6-37452] 
Alanine aminotransferaseUI/L, median value [range] 55 [12-99] 
Aspartate aminotransferase UI/L, median value [range] 55.5 [14-135] 
Alkaline Fosfatase UI/L, median value [range] 163.5 [73-333] 
Gamma Glutamyltranspeptidase UI/L, median value [range] 65 [30-244] 
Creatinine mg/dL median value [range] 0.77 [0.5-1.6] 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV: Hepatitis C Virus. HBV: Hepatitis B Virus. NA: Not applicable. BCLC: Barcelona Clínic Liver Cancer. 
ECOG: Eastern Cooperative Oncology Group. 
Table 2: The baseline clinical and biochemistry characteristics of 
the whole patients. 
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Number 
of  patient 
 
Number of  
hepatic 
lesions 
HCC type 
Diameter 
of the 
biggest  
measurable 
lesion 
(mm) 
Macrovascular 
invasion 
Extrahepatic 
Metastases Child-Pugh ECOG-PS 
BCLC 
Stage 
1 1 Infiltrative  Yes No B (7 points) 1 C 
2 1 Infiltrative  Yes No A 0 C 
3 8 Nodular 40 No No A 0 B 
4 1 
Infiltrative 
and 
nodular 
75 Yes No A 0 C 
5 0 Nodular 19 No Yes (peritoneal) No cirrhosis 0 C 
6 2 Nodular 32 Yes No A 0 C 
7 1 Nodular 21 No Yes (lung) A 0 C 
8 1 
Infiltrative 
and 
nodular 
23 Yes No A 0 C 
9 4 
Infiltrative 
and 
nodular 
20 Yes No A 0 C 
10 1 Infiltrative  Yes No A 0 C 
 
 
 
 
 
 
 
 
Number 
of  patient 
 
Number of  
hepatic 
lesions 
HCC type 
Diameter 
of the 
biggest  
measurable 
lesion 
(mm) 
Macrovascular 
invasion 
Extrahepatic 
Metastases Child-Pugh ECOG-PS 
BCLC 
Stage 
11 1 Nodular 110 No No A 0 B 
12 3 
Infiltrative 
and nodular 
43 Yes No A 0 C 
Table 3a Baseline clinical and radiological characteristics of the patients finally included in the study. Patients with 
complete disappearance of lesions. 
Table 3b Baseline clinical and radiological characteristics of the patients finally included in the study. Patients with 
residual scar stable for more than 2 years. 
BCLC: Barcelona Clínic Liver Cancer. ECOG: Eastern Cooperative Oncology Group. 
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Supplementary Figure 1: 
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Supplementary Figure 2: 
  
  
 
 
  
Supplementary Figure 1.  
Computed tomography of a biopsy proven hepatocellular carcinoma. Some heterogeneous arterial 
enhancing mass (arrowheads in supplementary figure 1a) with no convincing washout (arrowheads in 
supplementary figure 1a) can be detected on the anterior aspect of the left hepatic lobe. An expansive left 
portal vein thrombosis can be noted (arrowheads in supplementary figure 1c). After 6 months of Sorafenib 
treatment, only a residual scar-like 12 mm in size and a segmental atrophy of left hepatic lobe can be 
distinguished (arrowheads in supplementary figure 1d). The left portal vein thrombosis was replaced by a 
linear calcification (arrow in supplementary figure 1d).  
Supplementary Figure 2 
Computed tomography of 11 cm infiltrative hepatocellular carcinoma involving both hepatic lobes. The lesion 
displays arterial enhancement (arrowheads in supplementary figure 2a) followed by heterogenous washout 
(arrowheads in supplementary figure 2b). After 2 years of sorafenib, the lesion vanished. A capsular 
retraction on the previous tumoral area together with a residual 21 mm size nodular area non-enhancing 
neither on arterial phase (arrowheads in Supplementary figure 2c) nor in venous phase (arrowheads in 
supplementary figure 2d) stable over time, were considered residual features. 
a b 
c d 
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Supplementary Table 1: 
 
TRIAL AUTHOR JOURNAL YEAR 
Tamoxifen vs. placebo Castells A et al. Gastroenterology 1995 
Transarterial Embolization vs. placebo Bruix J et al. Hepatology 1998 
Interferon vs. placebo Llovet JM et al. Hepatology 2000 
Tamoxifen vs. placebo Liu CL et al. Am J Gastroenterol 2000 
Transarterial chemoembolization vs. placebo Lo C et al. Hepatology 2002 
Octreotide vs. placebo Yuen M et al. Hepatology 2002 
Vitamin K3 vs. placebo Sarin SK et al. J Gastroenterol Hepatol 2006 
Octreotide vs. placebo Becker G et al. Hepatology 2007 
Sorafenib vs. placebo Llovet JM et al. N Eng J Med 2008 
Octreotide vs. placebo Barbare JC et al. Eur J Cancer 2009 
Sorafenib vs. placebo in Asia-Pacific region Cheng Al et al. Lancet Oncology 2009 
Thymostimulin vs. placebo Dollinger MM et al. BMC Cancer 2010 
Vandetanib vs. placebo Hsu C et al. J Hepatol 2012 
Brivanib vs. placebo Llovet JM et al. J Clin Oncology 2013 
Tivantinib vs. placebo Santoro A et al. Lancet Oncology 2013 
Everolimus vs. placebo Zhu AX et al. JAMA 2014 
Axitinib vs. placebo Kang Y-K et al. Ann Oncology 2015 
Ramucirumab vs. placebo Zhu AX et al. Lancet Oncology 2015 
Regorafenib vs. placebo Bruix J et al. Lancet Oncology 2016 
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Figure 1 HCC: Hepatocellular Carcinoma. CR: Complete Response.  
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Figure 3: AFP evolution before starting sorafenib, at first control, when CR was documented and after 
achieving CR.  
 
 
235x118mm (96 x 96 DPI)  
 
 
Page 34 of 38
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Computed tomography of an ill defined-infiltrative hepatocellular carcinoma located on segments IV and VIII 
of the liver. The arterial phase (figure 2a) shows areas of heterogeneous enhancement (arrowheads)  
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that displays scattered areas of washout on portal venous phase (arrowheads in figure 2b).  
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There was an expansive portal vein thrombosis, better seen on coronal reconstruction (arrow in figure 2c).  
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During Sorafenib treatment, the mass has vanished, persisting a wedge-shaped area of arterial 
enhancement (arrowheads in figure 2d)  
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with no washout related to residual non-expansive portal vein thrombosis (arrow in figure 2e).  
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